Prinivil: Advanced Blood Pressure Control for Cardiovascular Health
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.71 | $51.23 (0%) | 🛒 Add to cart |
| 60 | $1.21 | $102.46 $72.33 (29%) | 🛒 Add to cart |
| 90 | $1.05 | $153.69 $94.43 (39%) | 🛒 Add to cart |
| 120 | $0.95 | $204.92 $114.52 (44%) | 🛒 Add to cart |
| 180 | $0.88 | $307.39 $157.71 (49%) | 🛒 Add to cart |
| 270 | $0.83 | $461.08 $223.01 (52%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $614.77 $286.29 (53%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.33 | $40.18 (0%) | 🛒 Add to cart |
| 180 | $0.27 | $60.27 $48.22 (20%) | 🛒 Add to cart |
| 270 | $0.22 | $90.41 $59.27 (34%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $120.54 $70.32 (42%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.24 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $81.37 $69.31 (15%) | 🛒 Add to cart |
| 120 | $0.71 | $108.49 $85.39 (21%) | 🛒 Add to cart |
| 180 | $0.64 | $162.73 $114.52 (30%) | 🛒 Add to cart |
| 270 | $0.60 | $244.10 $161.73 (34%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $325.47 $207.94 (36%) | 🛒 Add to cart |
Synonyms | |||
Prinivil (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor prescribed for the management of hypertension, heart failure, and post-myocardial infarction care. As a first-line antihypertensive agent, it works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral arterial resistance and decreasing blood pressure. Its well-established efficacy, favorable safety profile, and once-daily dosing make it a cornerstone therapy in cardiovascular medicine. Clinical evidence supports its role in slowing the progression of renal disease in hypertensive patients with diabetes and improving survival rates following acute coronary events.
Features
- Active ingredient: Lisinopril
- Drug class: Angiotensin-converting enzyme (ACE) inhibitor
- Available in tablet formulations: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
- Standard once-daily dosing regimen
- Bioavailability: Approximately 25%
- Half-life: 12 hours
- Primarily renal excretion
- FDA-approved for hypertension, heart failure, and acute myocardial infarction
Benefits
- Effectively lowers systolic and diastolic blood pressure through renin-angiotensin-aldosterone system (RAAS) inhibition
- Reduces afterload in heart failure patients, improving cardiac output and functional capacity
- Demonstrates nephroprotective effects in diabetic patients with microalbuminuria
- Decreases mortality risk when initiated within 24 hours of acute myocardial infarction
- Provides 24-hour blood pressure control with single daily dosing
- Shows proven cardiovascular risk reduction beyond blood pressure lowering alone
Common use
Prinivil is primarily indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is routinely prescribed for management of congestive heart failure, particularly when conventional therapy with diuretics and digitalis provides insufficient symptomatic control. Following myocardial infarction, Prinivil is administered to hemodynamically stable patients to improve survival and reduce the incidence of subsequent ischemic events. Off-label uses include diabetic nephropathy management and prevention of migraine headaches in selected patient populations. The medication is typically incorporated into long-term treatment regimens for chronic cardiovascular conditions.
Dosage and direction
For hypertension management, the initial adult dosage is typically 10 mg once daily, which may be increased to 20-40 mg daily based on therapeutic response. Dosage adjustments are necessary in patients with renal impairment, with recommended starting doses of 2.5-5 mg in those with creatinine clearance below 30 mL/min. Heart failure patients usually begin with 2.5-5 mg daily under close medical supervision, with gradual titration to a maximum of 40 mg daily. Post-myocardial infarction patients receive 5 mg within 24 hours of symptom onset, followed by 5 mg after 24 hours, 10 mg after 48 hours, and maintenance dosing of 10 mg daily. Prinivil should be taken consistently either with or without food at approximately the same time each day.
Precautions
Patients should undergo baseline renal function assessment and serum electrolyte evaluation before initiation and periodically during therapy. Volume-depleted patients require careful monitoring during initial dosing due to risk of symptomatic hypotension. Regular blood pressure measurements are essential during dosage titration. Renal function should be closely monitored in patients with pre-existing renal impairment, congestive heart failure, or collagen vascular diseases. Potassium supplements and potassium-sparing diuretics should generally be avoided unless hypokalemia develops. Angioedema has been reported with ACE inhibitors and may occur at any time during treatment, requiring immediate discontinuation if involvement of the tongue, glottis, or larynx occurs.
Contraindications
Prinivil is contraindicated in patients with known hypersensitivity to lisinopril or any other ACE inhibitor. History of angioedema related to previous ACE inhibitor therapy represents an absolute contraindication. The medication should not be used during pregnancy, particularly during the second and third trimesters, due to risk of fetal injury and death. Bilateral renal artery stenosis or stenosis in a solitary kidney constitutes another contraindication due to risk of acute renal failure. Concomitant use with aliskiren in patients with diabetes is contraindicated.
Possible side effect
The most common adverse reactions include dizziness (6-12%), headache (5-9%), fatigue (3-5%), and cough (3-9%). Hypotension may occur, particularly in volume-depleted patients or those with heart failure. Gastrointestinal effects such as nausea (2-4%) and diarrhea (2-3%) have been reported. Hyperkalemia may develop, especially in patients with renal impairment or diabetes. Rash (1-2%) and orthostatic effects occur less frequently. Rare but serious side effects include angioedema (0.1-0.7%), neutropenia/agranulocytosis, hepatic failure, and pancreatitis. Renal impairment may occur, particularly in patients with pre-existing renal disease or those taking NSAIDs.
Drug interaction
Concomitant diuretic therapy may potentiate the hypotensive effect of Prinivil. Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect and increase risk of renal impairment. Potassium supplements, potassium-sparing diuretics, and salt substitutes containing potassium may increase the risk of hyperkalemia. Lithium levels may increase when co-administered with Prinivil. Concurrent use with other antihypertensive agents may result in additive hypotensive effects. Gold injections (sodium aurothiomalate) have been associated with nitritoid reactions. Dual blockade of the renin-angiotensin system with ARBs or aliskiren increases risks of hypotension, hyperkalemia, and renal impairment.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered near the time of the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable blood pressure control, and patients should establish routines to minimize missed doses. Healthcare providers should educate patients about appropriate management of missed doses during therapy initiation.
Overdose
Lisinopril overdose may manifest as severe hypotension, which represents the primary clinical concern. Bradycardia, circulatory shock, electrolyte disturbances, and renal failure may occur. Management involves aggressive volume expansion with normal saline solution. Vasopressor therapy may be required in refractory cases. Hemodialysis effectively removes lisinopril from the circulation, with clearance rates of approximately 50 mL/min. Patients should receive continuous hemodynamic monitoring in an intensive care setting. Serum electrolytes and renal function should be monitored closely following overdose. Symptomatic and supportive care remains the mainstay of treatment.
Storage
Prinivil tablets should be stored at controlled room temperature (20-25°C or 68-77°F) in their original container with the lid tightly closed. Protection from excessive moisture and light is essential for maintaining stability. The medication should be kept out of reach of children and pets. Tablets should not be used beyond the expiration date printed on the packaging. Proper storage conditions ensure maintenance of pharmaceutical quality and efficacy throughout the product’s shelf life.
Disclaimer
This information serves educational purposes only and does not constitute medical advice. Healthcare professionals should exercise clinical judgment when prescribing Prinivil, considering individual patient factors and contraindications. Patients must consult qualified healthcare providers for personalized medical recommendations. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Full prescribing information is available in the package insert or from the manufacturer.
Reviews
Clinical trials demonstrate Prinivil’s efficacy with 60-70% of hypertensive patients achieving blood pressure control at 20 mg daily dosage. Cardiology guidelines consistently recommend ACE inhibitors as first-line therapy based on extensive outcome data. The medication receives generally favorable reviews from prescribing physicians for its predictable pharmacokinetics and established safety profile. Patient satisfaction surveys indicate good tolerability, though the characteristic dry cough leads to discontinuation in approximately 3-5% of users. Long-term studies confirm sustained antihypertensive efficacy and cardiovascular protection over treatment periods exceeding five years.